---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-125188"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2026-11-10T21:15:23+00:00"
generated_at: "2026-11-10T21:16:05.646319+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NextCure Q3 net loss $6.8M; Avere merger financing grows to $820M, stockholder vote set for Dec 9

## Summary
- Financing commitments supporting Avere merger rise to ~$820M: prior $320M concurrent private placement plus a new $500M placement; ~$266M satisfied by canceling Avere convertible notes.
- Special stockholder meeting set for Dec 9, 2026 (record date Nov 3); S-4 declared effective Nov 6, 2026; combined company expected to trade on Nasdaq as AVRX.
- Q3 net loss $6.8M vs $8.6M a year ago; R&D $4.5M (-$1.6M YoY), G&A $4.4M (+$1.6M on $1.8M of merger legal fees), restructuring net gain $2.0M.
- Cash and marketable securities $8.7M at Sept 30, 2026, down $33.1M from $41.8M at Dec 31, 2025; $35.2M used in operations, offset by $1.2M ATM proceeds.
- Delaware Chancery final order Nov 2, 2026 validated July 2025 reverse split; LNCB74 IND transferred to LigaChem Oct 6; legacy holders to receive CVRs.

## SEC filing metadata
- accession: 0001104659-26-125188
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2026-11-10T21:15:23+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465926125188/0001104659-26-125188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465926125188/nxtc-20261110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-125188
- JSON: https://secwatch.observer/filing/0001104659-26-125188.json
- Plain text: https://secwatch.observer/filing/0001104659-26-125188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.